Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078.

Article  PubMed  Google Scholar 

Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The international neuroblastoma risk group (INRG) staging system: an INRG task force report. J Clin Oncol. 2009;27(2):298–303.

Article  PubMed  Google Scholar 

Chung C, Boterberg T, Lucas J, Panoff J, Valteau-Couanet D, Hero B, et al. Neuroblastoma. Pediatr Blood Cancer. 2021;68 Suppl 2(Suppl 2):e28473.

Article  PubMed  PubMed Central  Google Scholar 

Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, et al. Revised neuroblastoma risk classification system: a report from the Children’s Oncology Group. J Clin Oncol. 2021;39(29):3229–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17(4):369–86.

Article  CAS  PubMed  Google Scholar 

Pastorino F, Capasso M, Brignole C, Lasorsa VA, Bensa V, Perri P, et al. Therapeutic targeting of ALK in neuroblastoma: experience of Italian precision medicine in pediatric oncology. Cancers (Basel). 2023. https://doi.org/10.3390/cancers15030560.

Article  PubMed  PubMed Central  Google Scholar 

Flaadt T, Rehm J, Simon T, Hero B, Ladenstein RL, Lode HN, et al. Long-term outcomes and quality of life of high-risk neuroblastoma patients treated with a multimodal treatment including anti-GD2 immunotherapy: a retrospective cohort study. Cancers (Basel). 2025. https://doi.org/10.3390/cancers17010149.

Article  PubMed  PubMed Central  Google Scholar 

Henderson TO, Bardwell JK, Kao PC, Nathan PC, Landier W, Mostoufi-Moab S, et al. Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children’s Oncology Group. The Lancet Child & Adolescent Health. 2025;9(11):776–86.

Article  Google Scholar 

Smith V, Foster J. High-risk neuroblastoma treatment review. Children. 2018. https://doi.org/10.3390/children5090114.

Article  PubMed  PubMed Central  Google Scholar 

Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022;19(8):515–33.

Article  CAS  PubMed  Google Scholar 

Pinto N, Naranjo A, Hibbitts E, Kreissman SG, Granger MM, Irwin MS, et al. Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children’s Oncology Group (COG). Eur J Cancer. 2019;112:66–79.

Article  PubMed  PubMed Central  Google Scholar 

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol. 2004;22(24):4888–92.

Article  CAS  PubMed  Google Scholar 

Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2011;29(33):4351–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garaventa A, Poetschger U, Valteau-Couanet D, Luksch R, Castel V, Elliott M, et al. Randomized trial of two induction therapy regimens for high-risk neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. J Clin Oncol. 2021;39(23):2552–63.

Article  CAS  PubMed  Google Scholar 

Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J Nucl Med. 2013;54(4):541–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ladenstein R, Lambert B, Pötschger U, Castellani MR, Lewington V, Bar-Sever Z, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45(2):292–305.

Article  PubMed  Google Scholar 

Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, et al. Validation of postinduction curie scores in high-risk neuroblastoma: a Children’s Oncology Group and SIOPEN Group report on SIOPEN/HR-NBL1. J Nucl Med. 2018;59(3):502–8.

Article  CAS  PubMed  Google Scholar 

Yanik G, Naranjo A, Parisi MT, Shulkin BL, Nadel H, Gelfand MJ, et al. Impact of post-induction curie scores in high-risk neuroblastoma. Biol Blood Marrow Transplant. 2015;21(2):S107.

Article  Google Scholar 

Furman WL, Federico SM, McCarville MB, Shulkin BL, Davidoff AM, Krasin MJ, et al. A phase II trial of Hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma. Clin Cancer Res. 2019;25(21):6320–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furman WL, McCarville B, Shulkin BL, Davidoff A, Krasin M, Hsu CW, et al. Improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy: updated results of a phase II study using hu14.18K322A. J Clin Oncol. 2022;40(4):335–44.

Article  CAS  PubMed  Google Scholar 

Federico SM, Naranjo A, Zhang F, Marachelian A, Desai AV, Shimada H, et al. A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol. 2022;40(16_suppl):10003–10003.

Article  Google Scholar 

Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014;26(5):682–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellini A, Potschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, et al. Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). J Clin Oncol. 2021;39(30):3377–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosswog C, Fassunke J, Ernst A, Schomig-Markiefka B, Merkelbach-Bruse S, Bartenhagen C, et al. Genomic ALK alterations in primary and relapsed neuroblastoma. Br J Cancer. 2023;128(8):1559–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosswog C, Fassunke J, Ernst A, Schömig-Markiefka B, Merkelbach-Bruse S, Bartenhagen C, et al. Genomic ALK alterations in primary and relapsed neuroblastoma. Br J Cancer. 2023;128(8):1559–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fischer M, Moreno L, Ziegler DS, Marshall LV, Zwaan CM, Irwin MS, et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 2021;22(12):1764–76.

Article  CAS